@davo47,
- Provinding price targets in the spec sector is something somehow challenging due to the speculative nature of the segment, in particular when we are talking about "realistic" expectations. What is realistic for you may not be for me, however peer comparatives would give you a good picture in terms of what to expect and NAN and RAP are good examples to use.
Ann: Positive Safety Observations from Healthy Human Trials, page-23
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.89 |
Change
-0.040(2.08%) |
Mkt cap ! $174.4M | |||
| Open | High | Low | Value | Volume |
| $1.90 | $1.90 | $1.85 | $39.20K | 21.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 65 | $1.89 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.93 | 27360 | 1 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| EMV (ASX) Chart |
